Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences
NEW YORK, March 5, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MNK, MNTA, MYL, and NBIX which can be accessed for free by signing up to www.wallstequities.com/registration. Featured today on WallStEquities.com is the Generic Drugs space, which can be segmented into biosimilars, simple generic, and super generic. Under evaluation this morning are the following stocks: Mallinckrodt PLC (NYSE: MNK), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Mylan (NASDAQ: MYL), andNeurocrine Biosciences, Inc.. (NASDAQ: NBIX). All you have to do is sign up today for this free limited time offer by clicking the link below.
Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC's shares recorded a trading volume of 6.46 million shares last Friday, which was above their three months average volume of 3.66 million shares. The stock finished the trading session 4.02% higher at $16.31. The Company's shares are trading below their 50-day moving average by 18.50%. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, EMEA region, and internationally, have a Relative Strength Index (RSI) of 41.87.
On February 15th, 2018, Mallinckrodt announced that it will present on March 14th, 2018, at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel, 1601 Collins Ave. in Miami Beach, Florida. Matthew Harbaugh, Executive Vice President and CFO, and Steven Romano, M.D., Executive Vice President and Chief Scientific Officer, will represent the Company in a fireside chat at 10:15 a.m. ET that day. Get the full research report on MNK for free by clicking below at: www.wallstequities.com/registration/?symbol=MNK
On Friday, Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock ended the session 2.03% higher at $17.55. A total volume of 702,683 shares was traded. The Company's shares have gained 3.24% in the last month, 25.36% over the previous three months, and 18.58% over the past year. The stock is trading 12.67% above its 50-day moving average and 13.44% above its 200-day moving average. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 60.41.
On February 13th, 2018, Momenta Pharma (MNTA) announced that the US FDA has approved Sandoz's Abbreviated New Drug Application for Glatopa (glatiramer acetate injection) 40 mg/mL, and that Sandoz has initiated the launch of this product in the US. Glatopa was developed under a collaboration agreement between MNTA and Sandoz and is produced in the US.
On February 22nd, 2018, research firm Stifel upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $18 a share to $21 a share. The free technical report on MNTA can be accessed at: www.wallstequities.com/registration/?symbol=MNTA
Hatfield, the UK-based Mylan N.V.'s stock ended the day 0.69% higher at $40.97. A total volume of 7.05 million shares was traded, which was above their three months average volume of 6.08 million shares. The Company's shares have gained 11.15% over the previous three months. The stock is trading 7.83% above its 200-day moving average. Additionally, shares of Mylan, which together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide, have an RSI of 45.01.
On February 28th, 2018, Mylan announced that its CFO, Ken Parks, will present at the Raymond James 39th Annual Institutional Investors Conference on March 05th, 2018, at 1:40 p.m. ET in Orlando, Florida. The live webcast of the presentation can be accessed under the investor relations section of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on MYL at: www.wallstequities.com/registration/?symbol=MYL
Shares in San Diego, California headquartered Neurocrine Biosciences Inc. recorded a trading volume of 841,705 shares. The stock ended Friday's session 2.28% higher at $86.06. The Company's shares have gained 0.69% in the last month, 25.82% over the previous three months, and 94.79% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.02% and 36.87%, respectively. Furthermore, shares of Neurocrine Biosciences have an RSI of 56.60.
On February 13th, 2018, Neurocrine Biosciences announced its Q4 and year-end 2017 results. For Q4 2017, net income was $6.9 million; R&D expenses were $25.6 million; and sales, general and administrative (SG&A) expenses were $56.3 million. For the full year 2017, net loss was $(142.5) million, R&D expenses were $121.8 million, and SG&A expenses were $169.9 million. At December 31st, 2017, total assets were $817.6 million, including cash, investments and receivables of $797.6 million.
On February 22nd, 2018, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $95 a share to $110 a share. See the free research coverage on NBIX at: www.wallstequities.com/registration/?symbol=NBIX